Niagen Bioscience director granted 31,746 stock options
Niagen Bioscience director Steven D. Rubin received a compensation-related grant of stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Niagen Bioscience director Steven D. Rubin received a compensation-related grant of stock options. He was awarded 31,746 options to buy Common Stock at an exercise price of $3.45 per share. The options vest 100% on June 24, 2027 and expire on June 23, 2036. After this grant, he holds 31,746 derivative securities directly, with no open-market share purchases or sales reported in this filing.
Insider Trade Summary
Grant/Award: 31,746 shares
Grant/Award
1 txn
Insider
Rubin Steven D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 31,746 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 31,746 contracts (Direct)
Footnotes (1)
- F1. Option vests 100% on June 24, 2027.
Key Figures
Options granted: 31,746 options
Exercise price: $3.45 per share
Total derivative holdings after grant: 31,746 options
+2 more
5 metrics
Options granted
31,746 options
Stock Option (right to buy) grant to director Rubin
Exercise price
$3.45 per share
Conversion or exercise price for granted options
Total derivative holdings after grant
31,746 options
Total shares underlying derivative securities following transaction
Vesting date
June 24, 2027
Options vest 100% on this date per footnote
Expiration date
June 23, 2036
Expiration date of the granted stock options
Key Terms
Stock Option (right to buy), exercise price, expiration date, Common Stock, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy) linked to Common Stock"
exercise price financial
"conversion_or_exercise_price of $3.4500 per underlying share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date listed as 2036-06-23 for the option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title identified as Common Stock for the option"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description states Grant, award, or other acquisition"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Niagen Bioscience (NAGE) report for Steven D. Rubin?
Niagen Bioscience reported a grant of 31,746 stock options to director Steven D. Rubin. These derivative securities are a compensation award, not an open-market purchase or sale, and give him the right to buy Common Stock at a fixed exercise price.
How many stock options did Steven D. Rubin receive from Niagen Bioscience (NAGE)?
Steven D. Rubin received 31,746 stock options from Niagen Bioscience. Each option is a right to buy one share of Common Stock, bringing his directly held derivative position reported in this filing to 31,746 options following the grant.
What is the exercise price of the new Niagen Bioscience (NAGE) options granted to Steven D. Rubin?
The granted stock options have an exercise price of $3.45 per share. This means Rubin can purchase Niagen Bioscience Common Stock at $3.45 using these options, subject to vesting and before they reach their stated expiration date.
When do Steven D. Rubin’s new Niagen Bioscience (NAGE) options vest and expire?
The options vest 100% on June 24, 2027, according to the footnote. They carry an expiration date of June 23, 2036, giving Rubin a multi-year window after vesting to exercise his right to purchase Common Stock.
How many Niagen Bioscience (NAGE) derivative securities does Steven D. Rubin hold after this grant?
After the grant, Rubin is shown holding 31,746 derivative securities. These represent stock options linked to an equal number of underlying Common Stock shares, all held directly as reported, with no additional derivative positions listed in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates